Next Article in Journal
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Next Article in Special Issue
The Multifunctional Protein Kinase C-ε in Cancer Development and Progression
Previous Article in Journal
Head and Neck Sarcomas: A Comprehensive Cancer Center Experience
Cancers 2013, 5(3), 901-918; doi:10.3390/cancers5030901
Article

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

1
,
1,2,3
,
1
,
1
,
1
,
1
,
4
,
4,†
,
2,3,*  and 1,*
1 Centre for Chromosome Biology, School of Natural Sciences National University of Ireland Galway, Galway, Ireland 2 Department of Medicine, National University of Ireland Galway, Galway, Ireland 3 Department of Haematology, Galway University Hospital, Galway, Ireland 4 Nerviano Medical Sciences S.r.l., Via Pasteur 10, Nerviano 20014, Italy Present address: Boehringer Ingelheim RCV GmbH & Co KG, Vienna 1120, Austria
* Authors to whom correspondence should be addressed.
Received: 5 June 2013 / Revised: 4 July 2013 / Accepted: 4 July 2013 / Published: 24 July 2013
(This article belongs to the Special Issue Kinases and Cancer)
View Full-Text   |   Download PDF [734 KB, uploaded 24 July 2013]   |   Browse Figures

Abstract

Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma.
Keywords: apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle apoptosis; BCL2-family; DNA replication; multiple myeloma; kinase inhibitor; cell cycle
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Natoni, A.; Coyne, M.R.E.; Jacobsen, A.; Rainey, M.D.; O'Brien, G.; Healy, S.; Montagnoli, A.; Moll, J.; O'Dwyer, M.; Santocanale, C. Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. Cancers 2013, 5, 901-918.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert